3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Lymphoid
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Rhabdomyosarcoma
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Lymphoma
1
Gastro-enteropancreatic neuroendocrine tumor
1
Central Nervous System Neoplasms
1
Interventions
Rituximab
57
Cyclophosphamide
56
fludarabine
37
fludarabine phosphate
31
Filgrastim
27
Etoposide
22
Bortezomib
20
Melphalan
19
Gemcitabine
19
Cytarabine
17
Bendamustine Hydrochloride
17
Peripheral Blood Stem Cell Transplantation
16
Vincristine
15
pembrolizumab
14
aldesleukin
13
Prednisone
13
Doxorubicin
12
Dexamethasone
12
Busulfan
12
Whole-Body Irradiation
11
Vorinostat
11
Tacrolimus
11
Sirolimus
11
sargramostim
10
obinutuzumab
10
Lenalidomide
10
romidepsin
9
Radiotherapy
9
Rifampin
8
Paclitaxel
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Lymphoma
×
177Lu-octreotide, DOTA(0)-Tyr(3)-
×
Clear all
NCT06441331
2026-05-01
KinLET
ITM Solucin GmbH
Phase 1
Recruiting
20 enrolled